CD248 and breast carcinoma: To date, anti-CD248 antibodies such as 3K2L, scFv-1C1m, and scFv-7G22 have been applied to construct CAR-T cells for the therapy of breast cancer, lung cancer, and Ewing sarcoma, respectively (Ash et al., 2024; Fierle et al., 2021).